Law Firms Press Corcept Investors to Seek Lead Role in Securities Case Before April 21
The filings focus on claims Corcept promoted relacorilant as close to approval despite FDA feedback that its trial data fell short.
Overview
- - Three shareholder firms issued notices Monday urging Corcept investors to contact them about lead-plaintiff bids ahead of the April 21, 2026 deadline.
- - The putative class covers people who bought Corcept stock from October 31, 2024 through December 30, 2025.
- - The complaint says Corcept told investors relacorilant was “approaching approval” based on “powerful evidence” even as the FDA warned on several occasions that the data was inadequate.
- - The Schall notice says the class is not yet certified, so investors are not represented by counsel at this stage, and serving as lead plaintiff is not required to share in any recovery.
- - The firms say investors may seek to recover losses they claim followed the market learning the alleged truth about relacorilant and the strength of its clinical evidence.